Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

49.2K
Overview
49.2K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

121
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
121
Cancer Vaccines01:30

Cancer Vaccines

621
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
621
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

920
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
920
Cross-reactivity00:42

Cross-reactivity

32.1K
Overview
32.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current progress in developing mRNA-lipid nanoparticle vaccines against human bacterial pathogens.

Clinical microbiology reviews·2026
Same author

Overcoming methicillin resistance in Staphylococcus aureus via metal ion disruption of bacterial metabolism.

npj antimicrobials and resistance·2026
Same author

Molecular characterization of covRS mutations in M1<sub>UK</sub> Streptococcus pyogenes.

FEBS open bio·2026
Same author

Newly identified antimicrobial activity of an 8-hydroxyquinoline-based ionophore against multidrug-resistant Enterococcus faecium and Staphylococcus aureus.

The Journal of antimicrobial chemotherapy·2026
Same author

Cross-clade vaccination to overcome sarbecovirus or merbecovirus neutralization gaps.

Cell reports·2026
Same author

Does the Magnitude of Change in Coronal Plane Alignment of the Knee Affect Clinical Outcomes in Functional and Mechanical Alignment Total Knee Arthroplasty?

The Journal of arthroplasty·2026

Related Experiment Video

Updated: Nov 16, 2025

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.2K

A multivalent T-antigen-based vaccine for Group A Streptococcus.

Jacelyn M S Loh1,2, Tania Rivera-Hernandez3,4, Reuben McGregor5,6

  • 1Department of Molecular Medicine & Pathology, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand. mj.loh@auckland.ac.nz.

Scientific Reports
|February 24, 2021
PubMed
Summary

A novel multivalent vaccine targeting T-antigens, the main component of Group A Streptococcus (GAS) pili, shows promise. This T-antigen vaccine elicits protective antibodies and demonstrates potential for preventing GAS infections.

More Related Videos

A Murine Model of Group B Streptococcus Vaginal Colonization
10:19

A Murine Model of Group B Streptococcus Vaginal Colonization

Published on: November 16, 2016

14.7K
Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells
09:25

Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells

Published on: August 19, 2016

11.2K

Related Experiment Videos

Last Updated: Nov 16, 2025

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.2K
A Murine Model of Group B Streptococcus Vaginal Colonization
10:19

A Murine Model of Group B Streptococcus Vaginal Colonization

Published on: November 16, 2016

14.7K
Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells
09:25

Implementation of a Permeable Membrane Insert-based Infection System to Study the Effects of Secreted Bacterial Toxins on Mammalian Host Cells

Published on: August 19, 2016

11.2K

Area of Science:

  • Microbiology
  • Vaccinology
  • Immunology

Background:

  • Group A Streptococcus (GAS) pili, particularly the T-antigen, are crucial for host adhesion and colonization during infection.
  • Currently, no licensed vaccines exist for GAS infections, highlighting a significant unmet medical need.
  • The T-antigen is a promising target for developing effective GAS vaccines.

Purpose of the Study:

  • To develop and evaluate a multivalent vaccine targeting T-antigens for the prevention of GAS infections.
  • To assess the immunogenicity and protective efficacy of novel recombinant T-antigen fusion proteins.

Main Methods:

  • Generation of recombinant multivalent vaccine proteins (TeeVax1, TeeVax2, TeeVax3) by fusing T-antigen domains.
  • Vaccination of rabbits and mice with the recombinant proteins.
  • Assessment of antibody responses, including opsonophagocytic activity.
  • Evaluation of protective efficacy against invasive GAS disease in a mouse model.

Main Results:

  • Vaccination with TeeVax1 induced opsonophagocytic antibodies in rabbits and conferred protection in mice against invasive GAS disease.
  • TeeVax2 and TeeVax3 were constructed to cover additional T-antigens.
  • A combination of TeeVax1-3 generated a robust antibody response in rabbits, cross-reactive to 21 T-antigens, achieving over 95% vaccine coverage.

Conclusions:

  • A T-antigen-based multivalent vaccine strategy is effective in generating broad and protective immune responses against GAS.
  • These findings support the potential of a T-antigen-based vaccine for the prevention of Group A Streptococcus infections.